Please enter the email address you used to register, then we will send you a link to choose a new password
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Gain Therapeutics (NASDAQ:GANX) with a Buy and lowers the price...
Gain Therapeutics announced the pricing of an underwritten public offering of (i) 7,116,547 shares of its common stock at a pub...
Gain expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock and pre...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $9 pr...
GT-02287 was generally well tolerated up to and including the highest planned dose level, and there were no serious adverse eve...